Medical Devices & Pharmaceuticals

Nanotechnologies hold enormous potential to revolutionise the field of medicine through manifold applications:

  • Improved, cost-effective tissue engineering and creation of bespoke implants are realised through the combination of nanomaterials’ size and physical properties in 3D printing, resulting in biomimetic solutions: the use of natural materials and scaffolds without their problems (i.e. contaminations, infections, carried by unsterile biological material).
  • Therapeutics are enhanced through both the improved targeting and bioavailability of existing medicinal substances, as well as the discovery of entirely new substances and nanomaterials, which introduces a range of advantages over classical drug-delivery methods, including the targeted delivery to diseased sites only, and the improved adsorption, distribution and duration of medicines in the body.
  • Diagnostics are improved by nanotechnology-based innovations ranging from the introduction of increased sensitivity and specificity, to advanced rapid screening processes enabled by lab-on-a-chip devise.

 

Nanotechnology enables the combination of hitherto separate approaches to health care by permitting the realisation of so-called ’theranostic’ applications, as well as targeted combination products.

Over 200 nanotechnology-enables products have already undergone full clinical trials and are benefitting patients through a reduction of side effects due to systemic toxicity, tailored drug release that ultimately enhances the patient’s quality of life, as well as tissue engineered scaffolding that stimulates bone growth and this significantly reduces a patient’s recovery time.

Related Links

News & Alerts

US FDA publishes Draft Guidance for Industry on Drug Products, Including Biological Products, that Contain Nanomaterials

The United States Federal Drug Administration has published a draft Guidance on Drug Products, Including Biological Products, that Contain Nanomaterials on 18 December 2017.

This Guidance for Industry outlines potential risk factors for drugs containing nanomaterials. It also provides recommendations on quality aspects, environmental impact as well as guidance for both non-clinical and clinical testing.

The document is now open for public comments for a period of 90 days, closing on 19 March 2018.

Safe by Design workshop slides published

NIA was part of a multi-project consortium that delivered the 2 day workshop "Nanomaterials: Industrial workshop on Safe by Design" in Bilbao on April 24-25, managed by the project Nanogentools.

Projects dedicated to building the concept and tools behind Safe by Design came together, including: